Hong Kong debut for PRC vaccine distributor
May 04, 2011 | BY
clpstaff &clp articlesChina NT Pharma Group Company (NT Pharma) has raised US$208 million in its initial public offering (IPO) on the Hong Kong Stock Exchange. The offering…
China NT Pharma Group Company (NT Pharma) has raised US$208 million in its initial public offering (IPO) on the Hong Kong Stock Exchange. The offering price was HK$4.54 per share.
The issuer is a large fully-integrated supply chain and sales provider of vaccines and pharmaceutical products in China. It plans to utilise the proceeds for expansion of the company's distribution network, infrastructure upgrade and growth of its promotion teams. Private equity firm Texas Pacific Group (TPG) will remain NT Pharma's second largest shareholder.The lead underwriters of the
transaction were UBS and Goldman Sachs.
Advising the issuer was a Freshfields Bruckhaus Deringer team led by partners Chris Wong and Calvin Lai. A Hong Kong-based Fried Frank Harris Shriver & Jacobson team, led by partners Victoria Lloyd and Joshua Wechsler represented the underwriters. Hong Kong-based partners Scott Jalowayski, Paul Boltz and Brian Schwarzwalder of Ropes & Gray acted for TPG.
This premium content is reserved for
China Law & Practice Subscribers.
A Premium Subscription Provides:
- A database of over 3,000 essential documents including key PRC legislation translated into English
- A choice of newsletters to alert you to changes affecting your business including sector specific updates
- Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
Already a subscriber? Log In Now